000 01413 a2200385 4500
005 20250515064243.0
264 0 _c20070809
008 200708s 0 0 eng d
022 _a0013-9580
024 7 _a10.1111/j.1528-1167.2007.01086.x
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aChadwick, David
245 0 0 _aChoosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients.
_h[electronic resource]
260 _bEpilepsia
_cJul 2007
300 _a1259-63 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAnticonvulsants
_xeconomics
650 0 4 _aCarbamazepine
_xeconomics
650 0 4 _aCost-Benefit Analysis
650 0 4 _aDrug Costs
650 0 4 _aDrug Industry
_xeconomics
650 0 4 _aEpilepsies, Partial
_xdrug therapy
650 0 4 _aEpilepsy
_xdrug therapy
650 0 4 _aEpilepsy, Generalized
_xdrug therapy
650 0 4 _aHumans
650 0 4 _aLamotrigine
650 0 4 _aPractice Guidelines as Topic
650 0 4 _aRandomized Controlled Trials as Topic
_xeconomics
650 0 4 _aResearch Support as Topic
_xeconomics
650 0 4 _aTreatment Outcome
650 0 4 _aTriazines
_xeconomics
700 1 _aMarson, Tony
773 0 _tEpilepsia
_gvol. 48
_gno. 7
_gp. 1259-63
856 4 0 _uhttps://doi.org/10.1111/j.1528-1167.2007.01086.x
_zAvailable from publisher's website
999 _c16992116
_d16992116